A detailed history of Hillsdale Investment Management Inc. transactions in Alkermes Plc. stock. As of the latest transaction made, Hillsdale Investment Management Inc. holds 184,700 shares of ALKS stock, worth $4.49 Million. This represents 0.44% of its overall portfolio holdings.

Number of Shares
184,700
Previous 170,300 8.46%
Holding current value
$4.49 Million
Previous $4.72 Million 5.82%
% of portfolio
0.44%
Previous 0.4%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$26.4 - $32.56 $380,160 - $468,864
14,400 Added 8.46%
184,700 $5 Million
Q4 2023

Feb 09, 2024

SELL
$23.37 - $28.68 $7,011 - $8,604
-300 Reduced 0.18%
170,300 $4.72 Million
Q3 2023

Nov 09, 2023

SELL
$27.17 - $31.97 $5,705 - $6,713
-210 Reduced 0.12%
170,600 $4.78 Million
Q2 2023

Aug 11, 2023

BUY
$28.34 - $33.63 $3,117 - $3,699
110 Added 0.06%
170,810 $5.35 Million
Q1 2023

May 10, 2023

BUY
$25.31 - $29.02 $32,903 - $37,726
1,300 Added 0.77%
170,700 $4.81 Million
Q4 2022

Feb 13, 2023

SELL
$21.94 - $26.24 $546,306 - $653,376
-24,900 Reduced 12.82%
169,400 $4.43 Million
Q3 2022

Nov 10, 2022

SELL
$22.0 - $31.87 $110,000 - $159,350
-5,000 Reduced 2.51%
194,300 $4.34 Million
Q2 2022

Aug 12, 2022

BUY
$26.4 - $30.54 $1.42 Million - $1.65 Million
53,900 Added 37.07%
199,300 $5.94 Million
Q1 2022

Apr 28, 2022

SELL
$23.07 - $27.99 $41,526 - $50,382
-1,800 Reduced 1.22%
145,400 $3.83 Million
Q3 2021

Oct 21, 2021

BUY
$23.37 - $32.13 $2.84 Million - $3.9 Million
121,400 Added 470.54%
147,200 $4.54 Million
Q2 2021

Jul 29, 2021

BUY
$18.78 - $25.15 $484,524 - $648,870
25,800 New
25,800 $633,000

Others Institutions Holding ALKS

About Alkermes plc.


  • Ticker ALKS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 164,254,000
  • Market Cap $3.99B
  • Description
  • Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...
More about ALKS
Track This Portfolio

Track Hillsdale Investment Management Inc. Portfolio

Follow Hillsdale Investment Management Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hillsdale Investment Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Hillsdale Investment Management Inc. with notifications on news.